The oral CCR9 antagonist CCX282-B/vercirnon was successfully used in the TNFΔARE ileitis mouse model (63) as well as for the treatment of moderate-to-severe CD in a phase II study (64). This evidence concerns the gene CCR9 and Crohn ileitis.